Roth/MKM Out Positive on Bio-Path Holdings (BPTH), PT $40

Roth/MKM analyst Philip Shen reiterated a Buy rating and $40.00 price target on Bio-Path Holdings (NASDAQ: BPTH).

The analyst comments "BPTH safely completed treatment of dose cohort 2 in its Phase 1/1b trial evaluating BP1002 in rel/ref AML. As expected, dose level 2 had no dose limiting toxicity, and with dose cohorts 1 and 2 now complete, the trial will pause for a brief data review by the FDA before higher dose testing will continue at the next planned higher dose (60mg/m2). Upon Phase 1 completion (i.e., BP1002 monotherapy), the Phase 1b portion will assess BP1002 in combination with decitabine in the same disease setting."

For an analyst ratings summary and ratings history on Bio-Path Holdings click here. For more ratings news on Bio-Path Holdings click here.

Shares of Bio-Path Holdings closed at $3.24 yesterday.

You May Also Be Interested In

• New Street Research Upgrades Micron Technology (MU) to Buy
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat